Casi Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
CASI Pharmaceuticals, Inc. announced that ETP Global III Fund LP has purchased a $5 million convertible note, the fourth tranche of a $20 million financing, with conversion rights into ordinary shares.
CASI Pharmaceuticals, Inc. announced ETP Global III Fund L.P. purchased a $5 million convertible note, marking the third tranche of a $20 million financing.
CASI Pharmaceuticals, Inc. has secured a $5 million convertible promissory note from ETP Global III Fund LP to fund clinical trials in China and general operations.
CASI Pharmaceuticals, Inc. has secured a $5 million convertible promissory note from ETP Global III Fund LP, marking the first tranche of a $20 million financing initiative.
IDG-Accel China Growth Fund III and related entities have reported a decrease in their beneficial ownership of CASI Pharmaceuticals, Inc. ordinary shares to below 5% due to an increase in the total outstanding shares.
A group of investors, including Sparkle Byte Ltd. and individuals, updated their beneficial ownership in CASI Pharmaceuticals, Inc. to 5% due to an increase in the company's total outstanding shares.
Dr. Wei-Wu He, a director of CASI Pharmaceuticals, Inc., has submitted an updated non-binding proposal to acquire all publicly held ordinary shares for $1.15 per share in cash, aiming to take the company private.
Huiying Memorial Foundation, affiliated with Dr. Wei-Wu He, increased its stake in CASI Pharmaceuticals by purchasing 230,000 ordinary shares.
Panacea Venture Healthcare Fund II, L.P. and its affiliates, including James Huang, increased their beneficial ownership in CASI Pharmaceuticals, Inc. to 22.5% through recent share purchases and option grants.
Panacea Venture Healthcare Fund II, L.P. and related entities, led by James Huang, disclosed a 19.9% beneficial ownership in CASI Pharmaceuticals, Inc., with Huang joining the Board of Directors.
Huiying Memorial Foundation, a private family foundation associated with CASI Pharmaceuticals' founder, Dr. Wei-Wu He, has increased its beneficial ownership in the company through an open market purchase of 357,644 ordinary shares.
SCHEDULE 13D/A: IDG-Accel Funds Increase Stake in CASI Pharmaceuticals, Now Holding 5.9% of Ordinary Shares
IDG-Accel China Growth Fund III L.P. and IDG-Accel China III Investors L.P. have increased their beneficial ownership in CASI Pharmaceuticals, Inc. to 5.9% through recent open market purchases.